摘要
目的探究他克莫司用于老年激素抵抗型肾病综合征治疗中的临床疗效。方法选取本院2017年1月至2020年1月收治的老年激素抵抗型肾病综合征患者100例作为研究对象,并按照红蓝数字抽签法分为红字组和蓝字组,每组50例。两组均给予降脂与抗凝等基本治疗,在此基础上,红字组采用环磷酰胺治疗,蓝字组采用他克莫司治疗,比较两组治疗效果、不良反应发生率、尿蛋白水平与生化指标。结果蓝字组临床治疗总有效率为96.00%,明显高于红字组的80.00%,差异有统计学意义(P<0.05)。蓝字组不良反应发生率为6.00%,明显低于红字组的24.00%,差异有统计学意义(P<0.05)。蓝字组白蛋白、FPG、SCr均高于红字组,尿蛋白、TC、TG均低于红字组,差异具有统计学意义(P<0.05)。结论在基本治疗的基础上采用他克莫司治疗老年激素抵抗型肾病综合征患者效果显著,还可有效调节尿蛋白水平与生化指标,降低不良反应发生率,值得临床推广应用。
Objective To investigate the clinical efficacy of tacrolimus in the treatment of senile hormone resistant nephrotic syndrome.Methods 100 elderly patients with hormone resistant nephrotic syndrome who were treated in our hospital from January 2017 to January 2020 were selected as the research subjects,and they were divided into the red character group and the blue character group according to the red-blue number lottery method,with 50 cases in each group.Both groups were treated with lipid-lowering and anticoagulant therapy,on this basis,the red character group was treated with cyclophosphamide,while the blue character group was treated with tacrolimus.The therapeutic effect,incidence of adverse reactions,urinary protein level and biochemical indexes between the two groups were compared.Results The total effective rate of the blue character group was 96.00%,which was significantly higher than 80.00%of the red character group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the blue character group was 6.00%,which was significantly lower than 24.00%in the red character group,the difference was statistically significant(P<0.05).Albumin,FPG and SCr in the blue character group were higher than those in the red character group,while urinary protein,TC and TG were higher than those in the red character group,the difference was statistically significant(P<0.05).Conclusion On the basis of basic treatment,tacroimus has significant effect on the treatment of elderly patients with hormone resistant nephrotic syndrome,and can effectively regulate the level of urinary protein and biochemical indexes,and reduce the incidence of adverse reactions,which is worthy of clinical application.
作者
赵鹏
ZHAO Peng(Department of Nephrology,the Second Affiliated Hospital of Shenyang Medical College,Shenyang,Liaoning,110031,China)
出处
《当代医学》
2021年第18期78-80,共3页
Contemporary Medicine
